JESSE FISHMAN: Open Payments
NPI 1801490081 · BROOMFIELD, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,657 in 122 payments from 22 companies in 2025. Trend: 2023 $22 · 2024 $1,076 · 2025 $2,657
Food & beverage: $2,657
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 20 | $400 |
| AstraZeneca Pharmaceuticals LP | 13 | $390 |
| GlaxoSmithKline, LLC. | 10 | $240 |
| Regeneron Healthcare Solutions, Inc. | 10 | $192 |
| Genentech USA, Inc. | 8 | $157 |
| CSL Behring | 7 | $148 |
| Amgen Inc. | 8 | $146 |
| Cycle Pharmaceuticals Inc | 7 | $141 |
| Grifols USA, LLC | 5 | $124 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $120 |
Products named: XOLAIR, TEZSPIRE, DUPIXENT, FASENRA, NUCALA, Sajazir, NEFFY, Prolastin-C Liquid.
Industry payments across CO — which companies pay providers there.
